Objective:
To discuss advancements in the management of dry eye disease (DED) as presented at SECO 2026.
Key Findings:
- New medications targeting specific root causes of dry eye disease are expected to be available in 2026.
- The TFOS DEWS III framework provides a structured approach to diagnosing and treating DED.
Interpretation:
The advancements in medication and the structured approach from TFOS DEWS III are expected to enhance the management of dry eye disease.
Limitations:
Conclusion:
The developments in 2026 signify a promising direction for more effective treatment of dry eye disease.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.